A Prospective Clinical Study of a Percutaneous Vascular Access System for Hemodialysis Catheters
- 209 Downloads
Dysfunctional or infected hemodialysis polyester-cuffed catheters often require removal and are dissected out. The DermaPort™, percutaneous vascular access system (PVAS) permanently integrates a titanium mesh with the skin forming a stable, sterile barrier that allows for catheter placement, adjustment, or catheter exchange. This study aimed to describe the use and clinical outcomes of the DermaPort PVAS.
Thirty-eight patients who were receiving hemodialysis via a tunneled catheter were enrolled in this prospective open-label study. Assessments were performed biweekly for the first month and monthly thereafter, which included physical examination of the site of implantation for infection, catheter blood flow, and need for interventions to maintain catheter patency. Patient satisfaction was assessed with a visual analog score.
Implantation of technical success was 100% with the implantation site demonstrating early tissue incorporation after 2 weeks and full incorporation within 4 weeks. The DermaPort™ successfully enabled 31 catheter exchanges and 10 repositions thru the port without dissection in 18 patients with nine repositions (90%) performed at bedside. The mean primary patency of the DermaPort™ was 172 ± 150 days, and mean secondary patency was 430 ± 203 days. There were no reportable serious adverse events in 12,100 catheter days of use and zero explantations of the device attributed to infection. The observed catheter infection rate was 0.33/1000 days.
The DermaPort™ system can be effectively implanted and facilitates catheter interventions in hemodialysis patients requiring long-term catheter use and has a lower infection rate than historical catheter infection rates.
Clinical Trial Protocol Number DermaPort-001 (no clinicaltrials.gov number as study was performed 9 years ago).
Health Canada Reference Application Number: 118393.
KeywordsCatheter Clinical Dialysis Hemodialysis Percutaneous port
Percutaneous vascular access system
Blood flow rate
Tunneled dialysis catheters
Visual analog scales
The authors acknowledge the following people for their help in this study: Anna-Marie Sutherland (Former Clinical Coordinator, Lakeridge Health); Abe Janis (Former Technical Liaison for Scientific Development, DermaPort, Inc.). We thank Richard Holcomb for statistical support of this work.
Compliance with Ethical Standards
Conflicts of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
We acknowledge DermaPort, Inc. for funding this clinical trial. We also thank the Alfred Mann Institute for Biomedical Research at the University of Southern California for support of this paper. Dheeraj K. Rajan, Murray Asch, and Andrew Steele were paid consultants to DermaPort, Inc.
Informed consent was obtained from all individual participants included in the study.
- 7.Janis AD, Kunz LL, Porter C, Moran B, Mayton C, Richmond KN. Biomaterial prevents epidermal downgrowth along a percutaneous implant in rabbits. In: BioMedical engineering society annual fall meeting. Los Angeles (2007).Google Scholar
- 8.Janis AD, Kunz LL, Porter C, Moran B, Mayton C, Richmond KN, editors. Percutaneously implanted titanium mesh biomaterial reestablishes an epidermal seal by 3 weeks in rabbits. In: BioMedical engineering society annual fall meeting. Los Angeles (2007).Google Scholar
- 9.Grant S, Aitchison T, Henderson E, Christie J, Zare S, McMurray J, et al. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest. 1999;116(5):1208–17. https://doi.org/10.1378/chest.116.5.1208.CrossRefPubMedGoogle Scholar
- 11.Griffiths RI, Newsome BB, Block GA, Herbert RJ, Danese MD. Patterns of hemodialysis catheter dysfunction defined according to national kidney foundation guidelines as blood flow < 300 mL/min. Int J Nephrol. 2011;2011:891259. https://doi.org/10.4061/2011/891259.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Hemmelgarn BR, Moist L, Pilkey RM, Lok C, Dorval M, Tam PY, et al. Prevention of catheter lumen occlusion with rT-PA versus heparin (pre-CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrol. 2006;7:8. https://doi.org/10.1186/1471-2369-7-8.CrossRefPubMedPubMedCentralGoogle Scholar